Priority A — High-Risk Patients

PCSK9 Inhibitors: Who Qualifies and What to Expect

Who it's for: Secondary prevention patients, very high cardiovascular risk, familial hypercholesterolemia.

Find what's right for you — take the quiz

What the evidence says

FOURIER: Evolocumab on top of statins drove LDL very low and reduced cardiovascular events in ASCVD patients.

ODYSSEY OUTCOMES: Alirocumab reduced major adverse cardiovascular events after ACS.

Injectable medications given every 2–4 weeks, requiring clinician evaluation.

⚠ Safety & contraindications

— Injection site reactions are the most common side effect.

— Cost and access can be barriers — insurance coverage varies.

— Must be prescribed and managed by a clinician.

Frequently asked questions

Are PCSK9 inhibitors safe long-term?

FOURIER-OLE provides reassuring long-term safety data, though ongoing monitoring is standard.

How much do PCSK9 inhibitors cost?

List prices can be high, but assistance programs and insurance coverage have improved.

Medical Disclaimer: Educational only. Not medical advice. Talk to a licensed clinician before starting or changing any medication or supplement. Dietary supplements are not reviewed or approved for effectiveness by the FDA before they are sold.